These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37903733)

  • 1. Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.
    Pozorski V; Park Y; Mohamoud Y; Tesfamichael D; Emamekhoo H; Birbrair A; Albertini MR; Ma VT
    Pigment Cell Melanoma Res; 2023 Nov; 36(6):501-511. PubMed ID: 37903733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines.
    Gil L; Alves FR; Silva D; Fernandes I; Fontes-Sousa M; Alves M; Papoila A; Da Luz R
    Cureus; 2022 Feb; 14(2):e22224. PubMed ID: 35340486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.
    Ye M; Huang A; Yuan B; Tan G; Ai J; Liu H
    Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):1971-1989. PubMed ID: 38315178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Zhuang TZ; Ravindranathan D; Liu Y; Martini DJ; Brown JT; Nazha B; Russler G; Yantorni LB; Caulfield S; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2023 Mar; 28(3):239-245. PubMed ID: 36427017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
    Furubayashi N; Minato A; Tomoda T; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Harada K; Kuroiwa K; Fujimoto N; Nakamura M;
    Anticancer Res; 2024 Apr; 44(4):1675-1681. PubMed ID: 38537962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
    Tucker MD; Brown LC; Chen YW; Kao C; Hirshman N; Kinsey EN; Ancell KK; Beckermann KE; Davis NB; McAlister R; Schaffer K; Armstrong AJ; Harrison MR; George DJ; Rathmell WK; Rini BI; Zhang T
    Biomark Res; 2021 Nov; 9(1):80. PubMed ID: 34732251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies.
    Nakamura Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M; Fujisawa Y
    Jpn J Clin Oncol; 2019 May; 49(5):431-437. PubMed ID: 30753621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
    Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
    Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis.
    Ma Y; Ma X; Wang J; Wu S; Wang J; Cao B
    World J Surg Oncol; 2022 Jul; 20(1):242. PubMed ID: 35897018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab.
    Beulque Y; Kinget L; Roussel E; Mobaraki S; Laenen A; Debruyne PR; Van Herck Y; Baldewijns M; Wozniak A; Garg AD; Zucman-Rossi J; Couchy G; Albersen M; De Wever L; Haaker L; Beuselinck B
    Acta Oncol; 2024 Aug; 63():658-668. PubMed ID: 39129249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Suzuki S; Abe T; Endo T; Kaya H; Kitabayashi T; Kawasaki Y; Yamada T
    Cancer Manag Res; 2022; 14():3293-3302. PubMed ID: 36452436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
    Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
    J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
    Gambale E; Maruzzo M; Messina C; De Gennaro Aquino I; Vascotto IA; Rossi V; Bimbatti D; Cavasin N; Messina M; Mennitto A; Rebuzzi SE; Nasso C; Mercinelli C; Maiorano BA; Fanelli M; Sorarù M; Scolari F; Mela MM; Galli L; Salfi A; Rizzo M; Puglisi S; Orlando V; Fornarini G; Rametta A; Giannatempo P; Cerbone L; Doni L; Roviello G; Pillozzi S; Antonuzzo L
    Clin Genitourin Cancer; 2024 Aug; 22(4):102099. PubMed ID: 38776583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
    Sacdalan DB; Lucero JA; Sacdalan DL
    Onco Targets Ther; 2018; 11():955-965. PubMed ID: 29503570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.